OBJECTIVE: Intravenous artesunate is commonly used in the emergency treatment of patients with severe falciparum malaria in Asia. The choice of doses used has been empirical. To inform dosage recommendations we assessed the pharmacokinetics of intravenous artesunate after the first dose. METHODS: As part of a clinical trial of artesunate in adults with severe falciparum malaria in western Thailand, we assayed plasma concentrations of artesunate and the principal biologically active metabolite dihydroartemisinin (DHA) in 17 patients given an initial dose of 2.4 mg/kg body weight of intravenous artesunate. Drug levels were measured using high performance liquid chromatography with mass spectroscopy-electrospray ionisation detection. RESULTS: Median (range) observed DHA Cmax was 2128 (513-5789) nmol/L, elimination half-life was 0.34 (0.14-0.87) h, and the time to the last detectable DHA was 2 h. CONCLUSION: The large inter-individual variability (10 fold) in DHA Cmax and AUC in patients with potentially lethal, severe malaria, suggests that 2.4 mg/kg should be the minimum daily dose in severe malaria.
OBJECTIVE: Intravenous artesunate is commonly used in the emergency treatment of patients with severe falciparum malaria in Asia. The choice of doses used has been empirical. To inform dosage recommendations we assessed the pharmacokinetics of intravenous artesunate after the first dose. METHODS: As part of a clinical trial of artesunate in adults with severe falciparum malaria in western Thailand, we assayed plasma concentrations of artesunate and the principal biologically active metabolite dihydroartemisinin (DHA) in 17 patients given an initial dose of 2.4 mg/kg body weight of intravenous artesunate. Drug levels were measured using high performance liquid chromatography with mass spectroscopy-electrospray ionisation detection. RESULTS: Median (range) observed DHA Cmax was 2128 (513-5789) nmol/L, elimination half-life was 0.34 (0.14-0.87) h, and the time to the last detectable DHA was 2 h. CONCLUSION: The large inter-individual variability (10 fold) in DHA Cmax and AUC in patients with potentially lethal, severe malaria, suggests that 2.4 mg/kg should be the minimum daily dose in severe malaria.
Authors: Tim Sangster; Mike Spence; Peta Sinclair; Richard Payne; Christopher Smith Journal: Rapid Commun Mass Spectrom Date: 2004 Impact factor: 2.419
Authors: D B Bethell; P Teja-Isavadharm; X T Cao; T T Pham; T T Ta; T N Tran; T T Nguyen; T P Pham; D Kyle; N P Day; N J White Journal: Trans R Soc Trop Med Hyg Date: 1997 Mar-Apr Impact factor: 2.184
Authors: K Silamut; R Hough; T Eggelte; S Pukrittayakamee; B Angus; N J White Journal: Trans R Soc Trop Med Hyg Date: 1995 Nov-Dec Impact factor: 2.184
Authors: K T Batty; L T Thu; T M Davis; K F Ilett; T X Mai; N C Hung; N P Tien; S M Powell; H V Thien; T Q Binh; N V Kim Journal: Br J Clin Pharmacol Date: 1998-02 Impact factor: 4.335
Authors: T T Hien; T M E Davis; L V Chuong; K F Ilett; D X T Sinh; N H Phu; C Agus; G M Chiswell; N J White; J Farrar Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191
Authors: P Newton; Y Suputtamongkol; P Teja-Isavadharm; S Pukrittayakamee; V Navaratnam; I Bates; N White Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: F Nosten; C Luxemburger; F O ter Kuile; C Woodrow; J P Eh; T Chongsuphajaisiddhi; N J White Journal: J Infect Dis Date: 1994-10 Impact factor: 5.226
Authors: Rahul P Bakshi; Elizabeth Nenortas; Abhai K Tripathi; David J Sullivan; Theresa A Shapiro Journal: Sci Transl Med Date: 2013-10-02 Impact factor: 17.956
Authors: Carrie A Morris; Marie A Onyamboko; Edmund Capparelli; Matthew A Koch; Joseph Atibu; Vicky Lokomba; Macaya Douoguih; Jennifer Hemingway-Foday; David Wesche; Robert W Ryder; Carl Bose; Linda Wright; Antoinette K Tshefu; Steven Meshnick; Lawrence Fleckenstein Journal: Malar J Date: 2011-05-08 Impact factor: 2.979
Authors: I C E Hendriksen; G Mtove; A Kent; S Gesase; H Reyburn; M M Lemnge; N Lindegardh; N P J Day; L von Seidlein; N J White; A M Dondorp; J Tarning Journal: Clin Pharmacol Ther Date: 2013-02-08 Impact factor: 6.875